Heterogeneity of metastatic gastric neuroendocrine tumor
https://doi.org/10.25789/YMJ.2019.68.35
Abstract
The purpose of the study was to demonstrate the effect of heterogeneity of a tumor and its metastases on the choice of treatment tactics in a clinical case.
About the Authors
V. S. Trifanov
Rostov Research Institute of Oncology
Russian Federation
Russian Federation
Trifanov Vladimir S. – Cand.Med.Sc., surgeon, senior researcher
tel. 89185544312
O. I. Kit
Rostov Research Institute of Oncology
Russian Federation
Russian Federation
Kit Oleg I. – D.Med.Sc., Professor, Corresponding Member of RAS, General Director
E. N. Kolesnikov
Rostov Research Institute of Oncology
Russian Federation
Russian Federation
Kolesnikov Evgeniy N. – Cand.Med. Sc., Head of Department of Abdominal Oncology No.1
tel. 89185538854
N. S. Karnaukhov
Rostov Research Institute of Oncology
Russian Federation
Russian Federation
Karnaukhov Nikolay S. – Cand.Med.Sc., Head of Pathomorphological Department
tel. 89185255325
E. M. Nepomnyashchaya
Rostov Research Institute of Oncology
Russian Federation
Russian Federation
Nepomnyashchaya Evgenia M. – D.Med.Sc., Professor, leading researcher
tel. 89034056515
N. N. Timoshkina
Rostov Research Institute of Oncology
Russian Federation
Russian Federation
Timoshkina Natalia N. – Cand.Biol.Sc., Head of Laboratory of Molecular Oncology
tel. 89094242763
A. V. Snezhko
Rostov State Medical University
Russian Federation
Russian Federation
Snezhko Aleksandr V. – D.Med. Sc., teaching assistant, Department of Oncology
tel. 89185131837
M. Yu. Mesheryakova
Rostov State Medical University
Russian Federation
Russian Federation
Mesheryakova Milana Yu. – student
tel. 89897108731
A. L. Bazaev
Rostov Research Institute of Oncology
Russian Federation
Russian Federation
Bazaev Adlan L. – senior fellow
tel. 89286146603
References
1. Gurevich L.E. Immunohistochemical determination of the expression of receptors for somatostatin type 1, 2A, 3 and 5 in neuroendocrine tumors of various localization and degree of malignancy / L.E. Gurevich // Clinical Medicine Almanac. – 2016. - № 4(15). – P. 11-23.
2. Kit O.I. Screening for a neuroendocrine component in gastric cancer / O.I. Kit, N.S. Karnaukhov, V.S. Trifanov // Modern problems of science and education. – 2016. - №5. –P. 61-65.
3. Trifanov V.S. Clinical and immunohistochemical analysis of pancreatic neuroendocrine tumors /V.S. Trifanov, O.I. Kit, E.N. Kolesnikov // Modern problems of science and education. – 2019. - №3. – P.126.
4. Chekhun V.F. Heterogeneity of the tumor - a dynamic state / V.F. Chekhun, S.D. Sherban, Z.D. Savtsova //Oncology. – 2012. - №3 (20). – P.26-37.
5. Alderton G. Tumour evolution: epigenetic and genetic heterogeneity in metastasis. Nat Rev Cancer. 2017; 2(17):141.
6. Hoshino A. Tumour exosome integrins determine organotropic metastasis. Nature. 2015; 527(7578):329-335.
7. Rosen C. The increasing complexity of the cancer stem cell paradigm. Science. 2009; 324(5935):1670-1673.
Review
For citations:
Trifanov V.S., Kit O.I., Kolesnikov E.N., Karnaukhov N.S., Nepomnyashchaya E.M., Timoshkina N.N., Snezhko A.V., Mesheryakova M.Yu., Bazaev A.L. Heterogeneity of metastatic gastric neuroendocrine tumor. Yakut Medical Journal. 2019;(4):124-126. https://doi.org/10.25789/YMJ.2019.68.35
Views:
6
Email this article 